MapLight Therapeutics (MPLT) Stock Analysis

What MapLight Therapeutics does

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.

Key metrics

ETFs linked to MPLT

Broad-market and Healthcare sector ETFs an investor holding MapLight Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MPLT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for MapLight Therapeutics?

MapLight Therapeutics trades under the ticker MPLT on NASDAQ.

Which exchange is MPLT listed on?

MPLT is listed on NASDAQ.

What sector does MapLight Therapeutics operate in?

MapLight Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MPLT in a portfolio?

PortView shows MPLT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.